Review Article
Split Viewer
Blood Res 2020; 55(S1):
Published online July 31, 2020
https://doi.org/10.5045/br.2020.S010
© The Korean Society of Hematology
Recent advances in the management of primary central nervous system lymphoma
Correspondence to : Yoon Seok Choi, M.D., Ph.D.
Department of Hematology-Oncology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, Korea
E-mail: wyfran@ajou.ac.kr
This is an Open Access article distributed unAcute myeloid leukemia, New FDA approvalsder the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal lymphoma primarily involving the brain, spinal cord, or leptomeninges. PCNSL is associated with a relatively poor prognosis compared to other extranodal diffuse large B-cell lymphomas. However, methotrexate-based induction chemotherapy followed by consolidative chemotherapy or high-dose therapy and autologous stem cell transplantation has improved the survival outcome, together with reduced neurotoxicity. Recent studies found that aberrant activation of the B-cell receptor-signaling pathway and activation of the NF-κB are frequent genetic alterations and could be good targets for the treatment of PCNSL. Herein, we have reviewed the current status and recent advances in the biology and management of PCNSL.
Keywords Primary central nervous system lymphoma, Chemotherapy, Rituximab, Autologous stem cell transplantation, Ibrutinib
PDF
Standard view
Export citation
Share Article
Review Article
Blood Res 2020; 55(S1): S58-S62
Published online July 31, 2020 https://doi.org/10.5045/br.2020.S010
Copyright © The Korean Society of Hematology.
Recent advances in the management of primary central nervous system lymphoma
Yoon Seok Choi
Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea
Correspondence to:Yoon Seok Choi, M.D., Ph.D.
Department of Hematology-Oncology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, Korea
E-mail: wyfran@ajou.ac.kr
This is an Open Access article distributed unAcute myeloid leukemia, New FDA approvalsder the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal lymphoma primarily involving the brain, spinal cord, or leptomeninges. PCNSL is associated with a relatively poor prognosis compared to other extranodal diffuse large B-cell lymphomas. However, methotrexate-based induction chemotherapy followed by consolidative chemotherapy or high-dose therapy and autologous stem cell transplantation has improved the survival outcome, together with reduced neurotoxicity. Recent studies found that aberrant activation of the B-cell receptor-signaling pathway and activation of the NF-κB are frequent genetic alterations and could be good targets for the treatment of PCNSL. Herein, we have reviewed the current status and recent advances in the biology and management of PCNSL.
Keywords: Primary central nervous system lymphoma, Chemotherapy, Rituximab, Autologous stem cell transplantation, Ibrutinib
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
Advances in the treatment of newly diagnosed primary central nervous system lymphomas
Liren Qian, Ciprian Tomuleasa, Ioan-Alexandru Florian, Jianliang Shen, Ioan-Stefan Florian, Mihnea Zdrenghea, and Delia Dima
Blood Res 2017; 52(3): 159-166 -
Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
Byung Woog Kang, Sang Kyun Sohn, Joon Ho Moon, Yee Soo Chae, Jong Gwang Kim, Soo Jung Lee, Won Seog Kim, Je-Jung Lee, Se Ryeon Lee, Keon Uk Park, Ho Sup Lee, Won Sik Lee, Jong-Ho Won, Moo-Rim Park, Jae-Yong Kwak, Min Kyoung Kim, Hyo Jung Kim, Sung Yong Oh, Hye Jin Kang, and Cheolwon Suh
Blood Res 2014; 49(1): 15-21 -
A Case of Mantle Cell Lymphoma Treated with Autologous Stem Cell Transplantation and Rituximab
So Yeon Oh, Moon Ju Jang, Sei Kyung Chang, Do yeon Oh, So Young Chong
Korean J Hematol 2006; 41(3): 215-219
